Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.